Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook

M Chianca, S L'Abbate, I Fabiani, A Aimo… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Human epidermal growth factor receptor two (HER2) target therapies have
drastically revolutionized the treatment of HER2-positive breast cancer. Starting with …
被引用次数：2 相关文章

Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook

M Chianca, S L'Abbate, I Fabiani… - Expert opinion on …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction Human epidermal growth factor receptor two (HER2) target therapies have
drastically revolutionized the treatment of HER2-positive breast cancer. Starting with …

Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook

M Chianca, S L'Abbate, I Fabiani, A Aimo… - EXPERT OPINION ON …, 2023 - iris.sssup.it
Introduction: Human epidermal growth factor receptor two (HER2) target therapies have
drastically revolutionized the treatment of HER2-positive breast cancer. Starting with …
[PDF] sssup.it

[PDF][PDF] Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook

M Chianca, S L'Abbate, I Fabiani, A Aimo, M Emdin… - Toxicology, 2023 - iris.sssup.it
Introduction: Human epidermal growth factor receptor two (HER2) target therapies have
drastically revolutionized the treatment of HER2-positive breast cancer. Starting with …